Preclinical studies demonstrate the effective use of IFN-γ blockade while preserving CAR-T cytotoxicity in hematologic malignancies (19, 20), though a critical role of the IFN-γ signaling pathway in mediating CAR-T cytotoxicity in solid tumors has been demonstrated both in vitro and in immunocompromised mice (21). This evidence concerns the gene IFNG and hematologic disorder.